查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1477979

结核分枝桿菌治疗市场：依产品类型、最终用户、地区 - 全球产业分析、规模、占有率、成长、趋势、预测，2024-2032 年

Mycobacterium Tuberculosis Treatment Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032
出版日期: | 出版商: Persistence Market Research | 英文 287 Pages | 商品交期: 2-5个工作天内

价格
简介目录

Persistence Market Research 的结核分枝桿菌治疗市场研究报告详细分析了 2024 年至 2032 年的市场趋势、成长动力和课题以及未来的技术创新。提供对市场当前状况和未来预测的洞察。

全球结核分枝桿菌药物市场预计将从2024年的21.3亿美元成长到2032年的24亿美元，复合年增长率为1.2%。

重要见解

  • 预计市场规模（2024年）：21.3亿美元
  • 预测市场规模（2032年）：24亿美元
  • 全球市场成长率（2024-2032年复合年增长率）：1.2%

结核分枝桿菌治疗市场 - 报告范围：

结核分枝桿菌是一种引起结核病的细菌，它主要影响肺部，但也可以侵入其他器官。本报告强调了推动结核分枝桿菌治疗需求的因素，包括全球结核病病例数量的增加、结核病研究资金的增加以及诊断技术的改进。

市场驱动因素：

由于多种因素，对结核分枝桿菌治疗的需求正在增加。这一增长是由全球结核病患者数量的增加、筛检和诊断工具的改进以及更快速和有效的药物治疗方案的开发所推动的。抗药性结核病的增加正在刺激对新治疗方法的研究，包括合併治疗和长期疫苗策略。此外，全球健康倡议和结核病计画资助正在显着促进市场扩张。

市场限制：

结核分枝桿菌治疗市场面临课题，例如先进的结核分枝桿菌药物成本高、低收入国家获得医疗设施的机会有限以及治疗不遵从率高。治疗抗药性结核病的复杂性和治疗时间的长短也阻碍了市场的成长。监管的复杂性和针对特定国家的政府政策可能会延迟新疗法的推出。

市场机会：

结核分枝桿菌治疗市场有重大创新机会。分子生物学和基因工程的进步提供了开发更有效对抗抗药性结核菌株的新疗法的潜力。公私伙伴关係和国际合作可以加速研究和开发工作，而加强公共卫生运动可以提高意识、改善早期发现和遵守治疗方案。

本报告解决的关键问题

  • 2024年至2032年结核分枝桿菌治疗市场的预期复合年增长率为何？
  • 推动结核分枝桿菌治疗市场成长的关键因素是什么？
  • 哪种治疗方式拥有最大的市场占有率？
  • 谁是全球结核分枝桿菌治疗市场的主要参与者？
  • 领先企业采取哪些策略来保持竞争力？

目录

第一章执行摘要

第二章市场概况

  • 市场范围/分类
  • 市场定义/范围/限制
  • 包容与排除

第 3 章主要市场趋势

  • 影响市场的主要趋势
  • 产品创新/发展趋势

第 4 章关键成功因素

  • 依地区划分的疾病流行病学
  • 监管场景
  • PESTLE分析
  • 波特的分析
  • 厂商主要促销策略
  • 供应链分析

第五章市场背景

  • 宏观经济因素
  • 预测变量 - 相关性和影响
  • 市场动态

第 6 章 COVID-19 危机分析

  • COVID-19 与影响分析
    • 依疾病划分的收入
    • 依治疗类型划分的收入
    • 依管理途径划分的收入
    • 依分销管道划分的收入
    • 依国家/地区划分的收入
  • 2024年市场情景

第七章全球结核分枝桿菌治疗市场需求分析

  • 过往市值分析（2019-2023）
  • 目前和未来的市值预测（2024-2032）
    • 同比增长趋势分析
    • 绝对量机会分析

第八章全球结核分枝桿菌治疗市场分析：依疾病分类

  • 简介/主要发现
  • 过去的市场规模分析：依疾病分类（2019-2023）
  • 目前和未来的市场规模分析和预测：依疾病分类（2024-2032）
    • 潜伏性结核病
    • 活动性结核病
  • 依疾病划分的市场吸引力分析

第九章全球结核分枝桿菌治疗市场分析：依治疗类型

  • 简介/主要发现
  • 历史市场规模分析：依治疗类型（2019-2023）
  • 目前和未来的市场规模分析和预测：依治疗类型（2024-2032）
    • 首选药物
    • 第二选择药物
  • 依治疗类型分析市场吸引力

第10章全球结核分枝桿菌治疗市场分析：依给药途径

  • 简介/主要发现
  • 过去的市场规模分析：依管理途径（2019-2023）
  • 目前和未来的市场规模分析和预测：依管理方式（2024-2032）
    • 口服
    • 静脉
    • 肌肉内
  • 依给药途径进行的市场吸引力分析

第十一章全球结核分枝桿菌治疗市场分析：依通路

  • 简介/主要发现
  • 过去的市场规模分析：依分销管道划分（2019-2023）
  • 目前和未来的市场规模分析和预测：依分销管道划分（2024-2032）
    • 医院药房
    • 网上药店
    • 零售药店
    • 企业及个人销售
  • 依分销管道划分的市场吸引力分析

第十二章全球结核分枝桿菌治疗市场分析：依地区

  • 介绍
  • 过去的市场规模分析：依地区（2019-2023）
  • 目前和未来的市场规模分析和预测：依地区（2024-2032）
    • 北美
    • 拉丁美洲
    • 欧洲
    • 东亚
    • 南亚
    • 大洋洲
    • 中东/非洲
  • 依地区划分的市场吸引力分析

第十三章北美结核病治疗市场分析

第十四章拉丁美洲结核分枝桿菌治疗市场分析

第十五章欧洲结核分枝桿菌治疗市场分析

第十六章南亚结核菌治疗市场分析

第十七章东亚结核病治疗市场分析

第十八章 大洋洲结核分枝桿菌治疗市场分析

第十九章中东与非洲结核分枝桿菌治疗市场分析

第二十章市场结构分析

  • 依公司层级进行市场分析
  • 主要参与者的市场占有率分析
  • 市场存在分析

第 21 章 竞争分析

  • 比赛仪表板
  • 竞争标桿
  • 衝突详情
    • AstraZeneca
    • Johnson & Johnson Private Limited
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma
    • Lupin
    • Allergan
    • Merck & Co., Inc.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Hikma Pharmaceuticals PLC
    • Cipla Inc.
    • Endo International plc
    • Otsuka Pharmaceutical Co., Ltd.
    • STI Pharma, LLC

第22章假设和缩写

第23章研究方法论

简介目录
Product Code: PMRREP33190

The Mycobacterium Tuberculosis Treatment Market report by Persistence Market Research provides an in-depth analysis of the market trends, growth drivers, challenges, and prospective innovations spanning from 2024 to 2032. It offers insights into the current landscape and future projections of the market.

The global market for Mycobacterium tuberculosis treatment is expected to achieve a compound annual growth rate (CAGR) of 1.2% from USD 2.13 billion in 2024 to USD 2.40 billion by 2032.

Key Insights:

  • Estimated Market Size (2024): USD 2.13 Billion
  • Projected Market Size (2032): USD 2.40 Billion
  • Global Market Growth Rate (CAGR 2024 to 2032): 1.2%

Mycobacterium Tuberculosis Treatment Market - Report Scope:

Mycobacterium tuberculosis is the bacterium that causes tuberculosis (TB), primarily affecting the lungs but can invade other organs. This report focuses on the drivers promoting the demand for TB treatment, including the global rise in TB cases, increased funding for TB research, and enhancements in diagnostic technologies.

Market Growth Drivers:

The demand for TB treatment is escalating due to several factors. The increase in TB cases globally, enhanced screening and diagnostic measures, and the development of faster-acting and more effective drug regimens drive this growth. The rise of drug-resistant TB forms has spurred research into novel treatment approaches, including combination therapies and longer-term vaccine strategies. Additionally, global health initiatives and funding for TB programs significantly propel market expansion.

Market Restraints:

The Mycobacterium Tuberculosis Treatment Market faces challenges such as the high cost of advanced TB drugs, limited access to medical facilities in low-income countries, and significant rates of treatment non-compliance. The complexity of managing drug-resistant TB and the long duration of treatment also hinder market growth. Regulatory complexities and varying government policies across countries can delay the introduction of new treatments.

Market Opportunities:

Significant opportunities exist for innovation within the TB treatment market. Advances in molecular biology and genetic engineering offer potential for developing new treatments that are more effective against drug-resistant strains of TB. Public-private partnerships and international collaborations can accelerate research and development efforts, while increasing public health campaigns can raise awareness and improve early detection and compliance with treatment protocols.

Key Questions Addressed in the Report:

  • What is the Expected CAGR of the Mycobacterium Tuberculosis Treatment Market from 2024 to 2032?
  • What are the Key Factors Driving the Growth of the Mycobacterium Tuberculosis Treatment Market?
  • Which Treatment Modality Holds the Largest Market Share?
  • Who are the Key Players in the Global Mycobacterium Tuberculosis Treatment Market?
  • What Strategies are Adopted by Leading Companies to Remain Competitive?

Competitive Landscape and Business Strategies:

Key players in the market include Johnson & Johnson, Sanofi, Bayer AG, and GlaxoSmithKline plc. These companies focus on innovations in TB treatment, market penetration in untapped regions, and forming strategic partnerships to stay competitive. For instance, Johnson & Johnson offers Sirturo for multi-drug resistant TB, and Sanofi has been involved in developing booster combinations to enhance treatment efficacy.

Key Companies Profiled:

  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Allergan
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Cipla Inc.
  • Endo International plc
  • Otsuka Pharmaceutical Co., Ltd.
  • STI Pharma, LLC

Mycobacterium Tuberculosis Treatment Market Segmentation:

By Disease Type:

  • Latent TB
  • Active TB

By Treatment Type:

  • First-Line of Drugs
  • Second-Line of Drugs

By Route of Administration:

  • Oral
  • Intravenous
  • Intramuscular

By Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Institutional and Retail Sales

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply-Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions & Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Disease Epidemiology, By Region
  • 4.2. Regulatory Scenario
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Analysis
  • 4.5. Key Promotional Strategies, by Manufacturers
  • 4.6. Supply Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure
    • 5.1.3. Global Infectious Disease Treatment Market
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Growing Burden of Tuberculosis Disease
    • 5.2.2. Increasing Research and Development Activities
    • 5.2.3. Adoption of Different Treatments for Infectious Disease
    • 5.2.4. Rising Government Support
    • 5.2.5. Increasing FDA Approvals of New Drugs
    • 5.2.6. Strategic Mergers and Acquisitions Among Local Manufacturers
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. Revenue By Disease Type
    • 6.1.2. Revenue By Treatment Type
    • 6.1.3. Revenue By Route of Administration
    • 6.1.4. Revenue By Distribution Channel
    • 6.1.5. Revenue By Country
  • 6.2. 2024 Market Scenario

7. Global Mycobacterium Tuberculosis Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Disease Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Disease Type, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Type, 2024-2032
    • 8.3.1. Latent TB
    • 8.3.2. Active TB
  • 8.4. Market Attractiveness Analysis By Disease Type

9. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Treatment Type

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment Type, 2024-2032
    • 9.3.1. First-Line of Drugs
    • 9.3.2. Second-Line of Drugs
  • 9.4. Market Attractiveness Analysis By Treatment Type

10. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2032
    • 10.3.1. Oral
    • 10.3.2. Intravenous
    • 10.3.3. Intramuscular
  • 10.4. Market Attractiveness Analysis By Route of Administration

11. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2032
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Online Pharmacies
    • 11.3.3. Retail Pharmacies
    • 11.3.4. Institutional and Retail Sales
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, by Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis By Region

13. North America Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Disease Type
    • 13.3.3. By Treatment Type
    • 13.3.4. By Route of Administration
    • 13.3.5. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Disease Type
    • 13.4.3. By Treatment Type
    • 13.4.4. By Route of Administration
    • 13.4.5. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. U.S. Mycobacterium Tuberculosis Treatment Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Disease Type
        • 13.8.1.2.2. By Treatment Type
        • 13.8.1.2.3. By Route of Administration
        • 13.8.1.2.4. By Distribution Channel
    • 13.8.2. Canada Mycobacterium Tuberculosis Treatment Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Disease Type
        • 13.8.2.2.2. By Treatment Type
        • 13.8.2.2.3. By Route of Administration
        • 13.8.2.2.4. By Distribution Channel

14. Latin America Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Rest of Latin America
    • 14.3.2. By Disease Type
    • 14.3.3. By Treatment Type
    • 14.3.4. By Route of Administration
    • 14.3.5. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Disease Type
    • 14.4.3. By Treatment Type
    • 14.4.4. By Route of Administration
    • 14.4.5. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Brazil Mycobacterium Tuberculosis Treatment Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Disease Type
        • 14.8.1.2.2. By Treatment Type
        • 14.8.1.2.3. By Route of Administration
        • 14.8.1.2.4. By Distribution Channel
    • 14.8.2. Argentina Mycobacterium Tuberculosis Treatment Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Disease Type
        • 14.8.2.2.2. By Treatment Type
        • 14.8.2.2.3. By Route of Administration
        • 14.8.2.2.4. Distribution Channel
    • 14.8.3. Mexico Mycobacterium Tuberculosis Treatment Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Disease Type
        • 14.8.3.2.2. By Treatment Type
        • 14.8.3.2.3. By Route of Administration
        • 14.8.3.2.4. By Distribution Channel

15. Europe Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. BENELUX
      • 15.3.1.7. Nordic Countries
      • 15.3.1.8. Russia
      • 15.3.1.9. Rest of Europe
    • 15.3.2. By Disease Type
    • 15.3.3. By Treatment Type
    • 15.3.4. By Route of Administration
    • 15.3.5. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Disease Type
    • 15.4.3. By Treatment Type
    • 15.4.4. By Route of Administration
    • 15.4.5. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Disease Type
        • 15.8.1.2.2. By Treatment Type
        • 15.8.1.2.3. By Route of Administration
        • 15.8.1.2.4. By Distribution Channel
    • 15.8.2. France Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Disease Type
        • 15.8.2.2.2. By Treatment Type
        • 15.8.2.2.3. By Route of Administration
        • 15.8.2.2.4. By Distribution Channel
    • 15.8.3. Italy Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Disease Type
        • 15.8.3.2.2. By Treatment Type
        • 15.8.3.2.3. By Route of Administration
        • 15.8.3.2.4. By Distribution Channel
    • 15.8.4. Spain Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Disease Type
        • 15.8.4.2.2. By Treatment Type
        • 15.8.4.2.3. By Route of Administration
        • 15.8.4.2.4. By Distribution Channel
    • 15.8.5. U.K. Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Disease Type
        • 15.8.5.2.2. By Treatment Type
        • 15.8.5.2.3. By Route of Administration
        • 15.8.5.2.4. By Distribution Channel
    • 15.8.6. Benelux Union Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Disease Type
        • 15.8.6.2.2. By Treatment Type
        • 15.8.6.2.3. By Route of Administration
        • 15.8.6.2.4. By Distribution Channel
    • 15.8.7. Nordic Countries Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Disease Type
        • 15.8.7.2.2. By Treatment Type
        • 15.8.7.2.3. By Route of Administration
        • 15.8.7.2.4. By Distribution Channel
    • 15.8.8. Russia Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.8.1. Introduction
      • 15.8.8.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.8.2.1. By Disease Type
        • 15.8.8.2.2. By Treatment Type
        • 15.8.8.2.3. By Route of Administration
        • 15.8.8.2.4. By Distribution Channel

16. South Asia Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Thailand
      • 16.3.1.3. Indonesia
      • 16.3.1.4. Malaysia
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Disease Type
    • 16.3.3. By Treatment Type
    • 16.3.4. By Route of Administration
    • 16.3.5. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Disease Type
    • 16.4.3. By Treatment Type
    • 16.4.4. By Route of Administration
    • 16.4.5. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Mycobacterium Tuberculosis Treatment Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Disease Type
        • 16.8.1.2.2. By Treatment Type
        • 16.8.1.2.3. By Route of Administration
        • 16.8.1.2.4. By Distribution Channel
    • 16.8.2. Indonesia Mycobacterium Tuberculosis Treatment Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Disease Type
        • 16.8.2.2.2. By Treatment Type
        • 16.8.2.2.3. By Route of Administration
        • 16.8.2.2.4. By Distribution Channel
    • 16.8.3. Malaysia Mycobacterium Tuberculosis Treatment Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Disease Type
        • 16.8.3.2.2. By Treatment Type
        • 16.8.3.2.3. By Route of Administration
        • 16.8.3.2.4. By Distribution Channel
        • 16.8.3.2.5. By Distribution Channel
    • 16.8.4. Thailand Mycobacterium Tuberculosis Treatment Market Analysis
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Disease Type
        • 16.8.4.2.2. By Treatment Type
        • 16.8.4.2.3. By Route of Administration
        • 16.8.4.2.4. By Distribution Channel

17. East Asia Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By Disease Type
    • 17.3.3. By Treatment Type
    • 17.3.4. By Route of Administration
    • 17.3.5. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Disease Type
    • 17.4.3. By Treatment Type
    • 17.4.4. By Route of Administration
    • 17.4.5. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. China Mycobacterium Tuberculosis Treatment Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Disease Type
        • 17.8.1.2.2. By Treatment Type
        • 17.8.1.2.3. By Route of Administration
        • 17.8.1.2.4. By Distribution Channel
    • 17.8.2. Japan Mycobacterium Tuberculosis Treatment Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Disease Type
        • 17.8.2.2.2. By Treatment Type
        • 17.8.2.2.3. By Route of Administration
        • 17.8.2.2.4. By Distribution Channel
    • 17.8.3. South Korea Mycobacterium Tuberculosis Treatment Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Disease Type
        • 17.8.3.2.2. By Treatment Type
        • 17.8.3.2.3. By Route of Administration
        • 17.8.3.2.4. By Distribution Channel

18. Oceania Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Disease Type
    • 18.3.3. By Treatment Type
    • 18.3.4. By Route of Administration
    • 18.3.5. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Disease Type
    • 18.4.3. By Treatment Type
    • 18.4.4. By Route of Administration
    • 18.4.5. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Mycobacterium Tuberculosis Treatment Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Disease Type
        • 18.8.1.2.2. By Treatment Type
        • 18.8.1.2.3. By Route of Administration
        • 18.8.1.2.4. By Distribution Channel
    • 18.8.2. New Zealand Mycobacterium Tuberculosis Treatment Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Disease Type
        • 18.8.2.2.2. By Treatment Type
        • 18.8.2.2.3. By Route of Administration
        • 18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkey
      • 19.3.1.3. North Africa
      • 19.3.1.4. South Africa
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By Disease Type
    • 19.3.3. By Treatment Type
    • 19.3.4. By Route of Administration
    • 19.3.5. By Distribution Channel
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Disease Type
    • 19.4.3. By Treatment Type
    • 19.4.4. By Route of Administration
    • 19.4.5. By Distribution Channel
  • 19.5. Market Trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Mycobacterium Tuberculosis Treatment Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Disease Type
        • 19.8.1.2.2. By Treatment Type
        • 19.8.1.2.3. By Route of Administration
        • 19.8.1.2.4. By Distribution Channel
    • 19.8.2. Turkey Mycobacterium Tuberculosis Treatment Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Disease Type
        • 19.8.2.2.2. By Treatment Type
        • 19.8.2.2.3. By Route of Administration
        • 19.8.2.2.4. By Distribution Channel
    • 19.8.3. North Africa Mycobacterium Tuberculosis Treatment Market Analysis
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Disease Type
        • 19.8.3.2.2. By Treatment Type
        • 19.8.3.2.3. By Route of Administration
        • 19.8.3.2.4. By Distribution Channel
    • 19.8.4. South Africa Mycobacterium Tuberculosis Treatment Market Analysis
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Disease Type
        • 19.8.4.2.2. By Treatment Type
        • 19.8.4.2.3. By Route of Administration
        • 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis
    • 20.3.1. Regional Footprint Analysis
    • 20.3.2. Channel Footprint Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. AstraZeneca
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Key Financials
      • 21.3.1.4. SWOT Analysis
      • 21.3.1.5. Sales Footprint
      • 21.3.1.6. Strategy Overview
      • 21.3.1.7. Key Developments
        • 21.3.1.7.1. Marketing Strategies
        • 21.3.1.7.2. Channel Strategies
    • 21.3.2. Johnson & Johnson Private Limited
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Key Financials
      • 21.3.2.4. SWOT Analysis
      • 21.3.2.5. Sales Footprint
      • 21.3.2.6. Strategy Overview
      • 21.3.2.7. Key Developments
        • 21.3.2.7.1. Marketing Strategies
        • 21.3.2.7.2. Channel Strategies
    • 21.3.3. Eli Lilly and Company
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Key Financials
      • 21.3.3.4. SWOT Analysis
      • 21.3.3.5. Sales Footprint
      • 21.3.3.6. Strategy Overview
      • 21.3.3.7. Key Developments
        • 21.3.3.7.1. Marketing Strategies
        • 21.3.3.7.2. Channel Strategies
    • 21.3.4. F. Hoffmann-La Roche Ltd.
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Key Financials
      • 21.3.4.4. SWOT Analysis
      • 21.3.4.5. Sales Footprint
      • 21.3.4.6. Strategy Overview
      • 21.3.4.7. Key Developments
        • 21.3.4.7.1. Marketing Strategies
        • 21.3.4.7.2. Channel Strategies
    • 21.3.5. Mylan N.V.
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Key Financials
      • 21.3.5.4. SWOT Analysis
      • 21.3.5.5. Sales Footprint
      • 21.3.5.6. Strategy Overview
      • 21.3.5.7. Key Developments
        • 21.3.5.7.1. Marketing Strategies
        • 21.3.5.7.2. Channel Strategies
    • 21.3.6. Teva Pharmaceutical Industries Ltd.
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Key Financials
      • 21.3.6.4. SWOT Analysis
      • 21.3.6.5. Sales Footprint
      • 21.3.6.6. Strategy Overview
      • 21.3.6.7. Key Developments
        • 21.3.6.7.1. Marketing Strategies
        • 21.3.6.7.2. Channel Strategies
    • 21.3.7. Sanofi
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Key Financials
      • 21.3.7.4. SWOT Analysis
      • 21.3.7.5. Sales Footprint
      • 21.3.7.6. Strategy Overview
      • 21.3.7.7. Key Developments
        • 21.3.7.7.1. Marketing Strategies
        • 21.3.7.7.2. Channel Strategies
    • 21.3.8. Novartis AG
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Key Financials
      • 21.3.8.4. SWOT Analysis
      • 21.3.8.5. Sales Footprint
      • 21.3.8.6. Strategy Overview
      • 21.3.8.7. Key Developments
        • 21.3.8.7.1. Marketing Strategies
        • 21.3.8.7.2. Channel Strategies
    • 21.3.9. Sun Pharmaceutical Industries Ltd.
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Key Financials
      • 21.3.9.4. SWOT Analysis
      • 21.3.9.5. Sales Footprint
      • 21.3.9.6. Strategy Overview
      • 21.3.9.7. Key Developments
        • 21.3.9.7.1. Marketing Strategies
        • 21.3.9.7.2. Channel Strategies
    • 21.3.10. Aurobindo Pharma
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Key Financials
      • 21.3.10.4. SWOT Analysis
      • 21.3.10.5. Sales Footprint
      • 21.3.10.6. Strategy Overview
      • 21.3.10.7. Key Developments
        • 21.3.10.7.1. Marketing Strategies
        • 21.3.10.7.2. Channel Strategies
    • 21.3.11. Lupin
      • 21.3.11.1. Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Key Financials
      • 21.3.11.4. SWOT Analysis
      • 21.3.11.5. Sales Footprint
      • 21.3.11.6. Strategy Overview
      • 21.3.11.7. Key Developments
        • 21.3.11.7.1. Marketing Strategies
        • 21.3.11.7.2. Channel Strategies
    • 21.3.12. Allergan
      • 21.3.12.1. Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Key Financials
      • 21.3.12.4. SWOT Analysis
      • 21.3.12.5. Sales Footprint
      • 21.3.12.6. Strategy Overview
      • 21.3.12.7. Key Developments
        • 21.3.12.7.1. Marketing Strategies
        • 21.3.12.7.2. Channel Strategies
    • 21.3.13. Merck & Co., Inc.
      • 21.3.13.1. Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Key Financials
      • 21.3.13.4. SWOT Analysis
      • 21.3.13.5. Sales Footprint
      • 21.3.13.6. Strategy Overview
      • 21.3.13.7. Key Developments
        • 21.3.13.7.1. Marketing Strategies
        • 21.3.13.7.2. Channel Strategies
    • 21.3.14. Pfizer Inc.
      • 21.3.14.1. Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Key Financials
      • 21.3.14.4. SWOT Analysis
      • 21.3.14.5. Sales Footprint
      • 21.3.14.6. Strategy Overview
      • 21.3.14.7. Key Developments
        • 21.3.14.7.1. Marketing Strategies
        • 21.3.14.7.2. Channel Strategies
    • 21.3.15. GlaxoSmithKline plc
      • 21.3.15.1. Overview
      • 21.3.15.2. Product Portfolio
      • 21.3.15.3. Key Financials
      • 21.3.15.4. SWOT Analysis
      • 21.3.15.5. Sales Footprint
      • 21.3.15.6. Strategy Overview
      • 21.3.15.7. Key Developments
        • 21.3.15.7.1. Marketing Strategies
        • 21.3.15.7.2. Channel Strategies
    • 21.3.16. Hikma Pharmaceuticals PLC
      • 21.3.16.1. Overview
      • 21.3.16.2. Product Portfolio
      • 21.3.16.3. Key Financials
      • 21.3.16.4. SWOT Analysis
      • 21.3.16.5. Sales Footprint
      • 21.3.16.6. Strategy Overview
      • 21.3.16.7. Key Developments
        • 21.3.16.7.1. Marketing Strategies
        • 21.3.16.7.2. Channel Strategies
    • 21.3.17. Cipla Inc.
      • 21.3.17.1. Overview
      • 21.3.17.2. Product Portfolio
      • 21.3.17.3. Key Financials
      • 21.3.17.4. SWOT Analysis
      • 21.3.17.5. Sales Footprint
      • 21.3.17.6. Strategy Overview
      • 21.3.17.7. Key Developments
        • 21.3.17.7.1. Marketing Strategies
        • 21.3.17.7.2. Channel Strategies
    • 21.3.18. Endo International plc
      • 21.3.18.1. Overview
      • 21.3.18.2. Product Portfolio
      • 21.3.18.3. Key Financials
      • 21.3.18.4. SWOT Analysis
      • 21.3.18.5. Sales Footprint
      • 21.3.18.6. Strategy Overview
      • 21.3.18.7. Key Developments
        • 21.3.18.7.1. Marketing Strategies
        • 21.3.18.7.2. Channel Strategies
    • 21.3.19. Otsuka Pharmaceutical Co., Ltd.
      • 21.3.19.1. Overview
      • 21.3.19.2. Product Portfolio
      • 21.3.19.3. Key Financials
      • 21.3.19.4. SWOT Analysis
      • 21.3.19.5. Sales Footprint
      • 21.3.19.6. Strategy Overview
      • 21.3.19.7. Key Developments
        • 21.3.19.7.1. Marketing Strategies
        • 21.3.19.7.2. Channel Strategies
    • 21.3.20. STI Pharma, LLC
      • 21.3.20.1. Overview
      • 21.3.20.2. Product Portfolio
      • 21.3.20.3. Key Financials
      • 21.3.20.4. SWOT Analysis
      • 21.3.20.5. Sales Footprint
      • 21.3.20.6. Strategy Overview
      • 21.3.20.7. Key Developments
        • 21.3.20.7.1. Marketing Strategies
        • 21.3.20.7.2. Channel Strategies

22. Assumptions and Acronyms Used

23. Research Methodology